Accepted at 5:08 a.m. Aug, 07, 2026 by braviboron
Author: aeast23
Related Note: 1693634259939
Rationale for change

Bisphosphonates increase risk of atypical fractures, they don't decrease risk

Text Text
Extra
Extra (Synced)
Empty field
Personal Notes
Empty field
Missed Questions
Empty field
eTG Complete
Empty field
Talley & O'Connor
Empty field
Additional Resources
Empty field
Additional Resources (Synced)
Empty field
Source
One by one
#Malleus_CM::#Card_Feature::Mnemonics #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Ibandronic_acid::05_Route/Frequency #Malleus_CM::#Yield::Medium #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Alendronate::06_Adverse_Effects #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Risedronate::04_Contraindications/Precautions #Malleus_CM::#Resources_by_Rotation::General_Practice #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Zoledronic_acid::04_Contraindications/Precautions #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Zoledronic_acid::02_Mechanism_of_Action #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Pamidronate::04_Contraindications/Precautions #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Pamidronate::02_Mechanism_of_Action #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Pamidronate::06_Adverse_Effects #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Ibandronic_acid::06_Adverse_Effects #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Ibandronic_acid::02_Mechanism_of_Action #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Risedronate::05_Route/Frequency #Malleus_CM::#OSCEs_&_Clinical_Reasoning::03_Counselling/Consent::General_Practice::Bisphosphonates #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Pamidronate::05_Route/Frequency #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Alendronate::04_Contraindications/Precautions #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Zoledronic_acid::05_Route/Frequency #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Ibandronic_acid::04_Contraindications/Precautions #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Zoledronic_acid::06_Adverse_Effects #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Risedronate::02_Mechanism_of_Action #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Alendronate::05_Route/Frequency #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Risedronate::06_Adverse_Effects #Malleus_CM::#Pharmacology::11_Endocrine_drugs::03_Drugs_affecting_bone::01_Bisphosphonates::Alendronate::02_Mechanism_of_Action